Medindia LOGIN REGISTER
Medindia
Advertisement

S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies

Tuesday, September 11, 2007 General News
Advertisement
SINGAPORE, Sept. 11 S*BIO Pte Ltd today announced thedevelopment of a novel and proprietary orally-administered compound, SB1518,for the treatment of myeloproliferative disorders (MPD) and certainhematological malignancies. MPD is believed to be caused by a specificmutation (V617F) of JAK2 and is a closely related group of hematologicalmalignancies in which the bone marrow develops and functions abnormally. MPDis characterised by an excess of blood cells and the three main disordersinclude polycythemia vera (excess red blood cell mass), essentialthrombocythemia (excess blood platelets) and myelofibrosis. S*BIO is aprivately-held biotech company focusing on the research and clinicaldevelopment of novel targeted small molecule drugs for the treatment ofcancer.
Advertisement

SB1518 is a small molecule JAK2-selective kinase inhibitor. It has highpotency against both the wild type JAK2 kinase and the JAK2 kinase with theactivating V617F mutation which is found in high frequencies among three typesof MPD and in some leukemias. By targeting the JAK2 activating mutation,SB1518 has the potential to interfere with a key mechanism driving theprogress of MPD and other diseases.
Advertisement

"SB1518 has demonstrated excellent anti-proliferative and anti-tumoractivity, combined with very good tolerability in relevant in vitro and invivo models. SB1518 will address an important unmet medical need due to thelack of specific and effective long-term medical treatment for patients withMPD," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "This promising new compoundis our second success in the last twelve months and represents an importantstep in building S*BIO's strong pipeline of proprietary, targeted anti-cancercompounds."

In addition to SB1518, S*BIO has a robust pipeline including SB939, thecompany's lead histone deacetylase (HDAC) inhibitor which is currently inPhase 1 clinical trials. S*BIO's target-driven approach to innovative smallmolecule therapies for cancer is built on a profound understanding of cancerbiology, which the company aggressively translates into "best-in-class" and"first-in-class" drugs. The company has a strong team of experienced drugdiscovery scientists and biologists, and state-of-the-art infrastructure whichincludes a comprehensive technology platform covering the drug discovery valuechain, from target identification and validation through lead optimisation topre-clinical and clinical development.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research andclinical development of novel targeted small molecule drugs for the treatmentof cancer with leading programs around histone deacetylases (HDAC) andkinases. Its lead candidate, SB939, has entered the clinic in 2Q 2007.

In line with its vision to be a leading fully-integrated oncology-focusedbiotech company in Asia Pacific, S*BIO has established a state-of-the-art R&Dinfrastructure, complemented by a strong clinical development team. S*BIO hasstrong linkages with a network of medical oncologists in Asia Pacific. Moreinformation about S*BIO can be found at http://www.sbio.com.S*BIO Pte Ltd: Russo Partners: Stephen Keith Rhind, Ph.D. Tony Russo +1 212-845-4251 Senior Vice President, [email protected] Corporate Development Andreas Marathovouniotis +1 212-845-4253 Tel: +65 6827 5000 (Singapore) [email protected] [email protected]

SOURCE S*BIO Pte Ltd
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close